GlycoVaxyn's technology paves the way for synthesizing bioconjugate material to levels previously unattainable and in a more cost-effective manner.

23.02.10 GlycoVaxyn's First Clinical Study with Bioconjugate Vaccine Initiated 06.10.09 GlycoVaxyn Appoints Renowned Vaccinologist Dr. Stanley A. Plotkin to Supervisory Board 05.03.09 GlycoVaxyn Announces its Series B Financing Round

GlycoVaxyn will be attending the BIO-Europe Spring 2010 in Barcelona, Spain on March 9,2010

GlycoVaxyn will be presenting at the VACCINE INNOVATION MEETING in Frankfurt, Germany on April 28, 2010

GlycoVaxyn will be attending the BIO International Convention in Chicago on May 3-6, 2010